Conmed (NASDAQ: CNMD) reported Q3 EPS of $0.46, in-line with the analyst estimate of $0.46. Revenue for the quarter came in at $202.3 million versus the consensus estimate of $198.46 million.

Based on current business trends, CONMED is raising the low end of its previously issued constant-currency sales guidance. The Company now expects full-year 2018 constant-currency and as adjusted(1) sales growth in the range of 6.5% to 7%, compared to the previous range of 6% to 7%. Based on recent exchange rates, the positive impact to 2018 sales from foreign exchange is anticipated to be between 0 and 50 basis points, which is consistent with the Company’s previously issuedguidance.

GUIDANCE:

Conmed sees FY2018 EPS of $2.15-$2.20, versus the consensus of $2.17.

For earnings history and earnings-related data on Conmed (CNMD) click here.